Mr Bertram Marks, Dr FEB May Introduction The incidence of oesophageal adenocarcinoma has increased six-fold over the past 40 years. Despite the increased prevalence, the 5-year mortality is still less than 15% and treatment doesn’t extend much beyond oesophagectomy. Co-activators of Rac1, DOCK2 and ELMO1, were found to be mutated in 17% of oesophageal adenocarcinomas…
Oesophagogastric
Advanced clinical stage not associated with poor outcomes
N Newton, AW Phillips, H Jaretzke, A Immanuel, N Hayes, SM Griffin BackgroundFollowing a diagnosis of oesophageal cancer UICC TNM staging guides treatment and informs prognosis. There is recognised variance between clinical staging (cTNM) and post-operative pathological staging ((y)pTNM). T3N3 oesophageal cancers have a 5-year survival of less than 25% in most studies; given the…